Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Gallium-68 radioisotope is a positron-emitting radionuclide with a physical half-life of approximately 68 minutes. It is produced from a ^68^Ge/^68^Ga generator, making it widely accessible for clinical PET imaging without the need for an onsite cyclotron[1][2][3][4][6][8]. Ga-68 is used to label a variety of molecules, most notably somatostatin analogs (e.g., Ga-68-DOTATATE, Ga-68-DOTATOC, Ga-68-DOTANOC), for high-resolution PET imaging of neuroendocrine tumors and other cancers[2][4][5][6][7][8][9][10]. The utility of Ga-68 radiopharmaceuticals lies in their rapid pharmacokinetics, high target-to-background ratios, and ability to provide sensitive and specific diagnostic information. However, Gallium-68 itself does not have biological activity, does not act as a protein or receptor, and is not a therapeutic target; its role is purely as a radiotracer label enabling molecular imaging in nuclear medicine.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Gallium-68 radioisotope (Ga-68).